Background Image
Table of Contents Table of Contents
Previous Page  96 / 113 Next Page
Information
Show Menu
Previous Page 96 / 113 Next Page
Page Background

96

[110] G. Tadini, D. Milani, F. Menni, L. Pezzani, C. Sabatini, and S. Esposito, “Is it time to change the

neurofibromatosis 1 diagnostic criteria?,”

Eur. J. Intern. Med.

, vol. 25, no. 6, pp. 506–510, Jul. 2014.

[111] M. Khodaee, “Painless cutaneous nodules,”

J. Fam. Pract.

, vol. 61, no. 8, pp. 489–491, Aug. 2012.

[112] L. K. Kriechbaumer, M. Susani, S. G. Kircher, and W. Happak, “Vaporization of cutaneous

neurofibromas with an erbium: yttrium-aluminum-garnet laser: a comparative histologic evaluation,”

Plast. Reconstr. Surg.

, vol. 129, no. 3, p. 602e–604e, Mar. 2012.

[113] Nederlandse Vereniging voor Dermatologie en Venereologie, “Richtlijn Laserbehandeling en

flitslamptherapie.” 2004.

[114] V. S. Warbey, R. E. Ferner, J. T. Dunn, E. Calonje, and M. J. O’Doherty, “[18F]FDG PET/CT in the

diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1,”

Eur. J. Nucl. Med.

Mol. Imaging

, vol. 36, no. 5, pp. 751–757, May 2009.

[115] C. E. Prada, F. A. Rangwala, L. J. Martin, A. M. Lovell, H. M. Saal, E. K. Schorry, and R. J. Hopkin,

“Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1,”

J.

Pediatr.

, vol. 160, no. 3, pp. 461–467, Mar. 2012.

[116] NVK and CBO, “Pijnmeting en behandeling van pijn bij kinderen.” 2007.

[117] D. A. Stevenson, D. Little, L. Armstrong, A. H. Crawford, D. Eastwood, J. M. Friedman, T. Greggi, G.

Gutierrez, K. Hunter-Schaedle, D. L. Kendler, M. Kolanczyk, F. Monsell, M. Oetgen, B. S. Richards, A.

Schindeler, E. K. Schorry, D. Wilkes, D. H. Viskochil, F.-C. Yang, and F. Elefteriou, “Approaches to treating

NF1 tibial pseudarthrosis: consensus from the Children’s Tumor Foundation NF1 Bone Abnormalities

Consortium,”

J. Pediatr. Orthop.

, vol. 33, no. 3, pp. 269–275, May 2013.

[118] N. G. Gandhi, “Treatment of neuro-ophthalmic and orbitofacial manifestations of neurofibromatosis

type 1,”

Curr. Opin. Ophthalmol.

, Jul. 2013.

[119] G. Nicolin, P. Parkin, D. Mabbott, D. Hargrave, U. Bartels, U. Tabori, J. Rutka, J. R. Buncic, and E.

Bouffet, “Natural history and outcome of optic pathway gliomas in children,”

Pediatr. Blood Cancer

, vol.

53, no. 7, pp. 1231–1237, Dec. 2009.

[120] L. Rehbock and R. F. Neuteboom, “Richtlijn: hoofdpijn bij kinderen.” Erasmus Medisch Centrum

Rotterdam, Jun-2013.

[121] Commissie Kwaliteit van de, Nederlandse Vereniging voor Neurologie, and Werkgroep Richtlijnen

Hoofdpijn, “Richtlijnen diagnostiek en behandeling chronisch recidiverende hoofdpijn zonder

neurologische afwijkingen.” 2007.

[122] I. Pascual-Castroviejo, S. I. Pascual-Pascual, R. Velázquez-Fragua, J. Viaño, and F. Carceller-Benito,

“[Aqueductal stenosis in the neurofibromatosis type 1. Presentation of 19 infantile patients],”

Rev.

Neurol.

, vol. 45, no. 1, pp. 18–21, Jul. 2007.

[123] A. P. Ostendorf, D. H. Gutmann, and J. L. Z. Weisenberg, “Epilepsy in individuals with

neurofibromatosis type 1,”

Epilepsia

, vol. 54, no. 10, pp. 1810–1814, Oct. 2013.

[124] M. Runke and V. Salanova, “Epilepsy due to a cortical malformation in a Neurofibromatosis type 1

patient,”

Seizure J. Br. Epilepsy Assoc.

, vol. 22, no. 6, pp. 476–479, Jul. 2013.

[125] C. Barba, T. Jacques, P. Kahane, T. Polster, J. Isnard, F. S. S. Leijten, C. Ozkara, L. Tassi, F. Giordano, M.

Castagna, A. John, B. Oz, C. Salon, N. Streichenberger, J. H. Cross, and R. Guerrini, “Epilepsy surgery in

Neurofibromatosis Type 1,”

Epilepsy Res.

, vol. 105, no. 3, pp. 384–395, Aug. 2013.

[126] Nederlandse Vereniging voor Neurologie en de Nederlandse Liga tegen Epilepsie, “Epilepsie.

Richtlijnen voor diagnostiek en behandeling.” 2006.

[127] T. L. Rosser, G. Vezina, and R. J. Packer, “Cerebrovascular abnormalities in a population of children

with neurofibromatosis type 1,”

Neurology

, vol. 64, no. 3, pp. 553–555, Feb. 2005.

[128] Kennisnetwerk CVA and Platvorm Vitale Vaten, “Zorgstandaard CVA/TIA.” Nov-2012.

[129] L. C. Krab, F. K. Aarsen, A. de Goede-Bolder, C. E. Catsman-Berrevoets, W. F. Arts, H. A. Moll, and Y.

Elgersma, “Impact of neurofibromatosis type 1 on school performance,”

J Child Neurol

, vol. 23, no. 9, pp.

1002–10, 2008.